News Search Results
Oct 28, 2025, 08:30 ET IVD Study Steps for Success: Safety and Quality of Global IVD Clinical Performance Studies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 28, 2025, 08:30 ET Where Will Your CGT Study Go? Solving the Site Capacity Challenge, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO and MILAN, Italy, Oct.
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
partnership will accelerate efficient and sustainable manufacturing of high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO and MILAN, Italy, Oct.
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET RheumaGen Presents HLA Gene-Editing Preclinical Data for Nearly Universal Autoimmune Disease Target at ACR Convergence 2025 Oral Session
University of Colorado Anschutz Medical Campus About RheumaGen, Inc.RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA),
More news about: RheumaGen, Inc.
Oct 28, 2025, 07:35 ET Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics
patients." About Myrio Therapeutics Myrio Therapeutics is a biotechnology company developing next-generation precision immunotherapies targeting oncogenic mutations using its proprietary pHLA binder technology. The company's
More news about: Myrio Therapeutics
Oct 28, 2025, 07:30 ET Syantra, Inc. Expands Reach and Impact to New Zealand through New Partnership with Breast Cancer Foundation NZ
CALGARY, AB, Oct. 28, 2025 /PRNewswire/ - Syantra, Inc., a precision biotechnology company revolutionizing early cancer detection, today announced a clinical research partnership with Breast Cancer Foundation NZ. The partnership
More news about: Syantra Inc.
Oct 28, 2025, 07:30 ET Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated
More news about: Oncolytics Biotech® Inc.
Oct 28, 2025, 07:00 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 28, 2025, 05:50 ET Clinical Trials Market Growing at 6.51% CAGR to 2030 Driven by Hybrid and Decentralized Trial Adoption | Mordor Intelligence Forecast
Phase (Phase I, Phase II), Service Types (Clinical Trial Site Management, Patient Recruitment & Retention), End User (Pharmaceutical Companies, Biotechnology Companies), Therapeutic Area (Oncology, Cardiology), and Geography (North America, Europe). Roche, Eli Lilly and Company,
More news about: Mordor Intelligence Private Limited
Oct 28, 2025, 05:28 ET WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health
Arabia. By leveraging WuXi AppTec's unique expertise and global network, the initiative aims to drive innovation and accelerate the growth of the biotechnology sector in Saudi Arabia.
More news about: WuXi AppTec
Oct 28, 2025, 05:00 ET WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health
Arabia. By leveraging WuXi AppTec's unique expertise and global network, the initiative aims to drive innovation and accelerate the growth of the biotechnology sector in Saudi Arabia.
More news about: WuXi AppTec
Oct 27, 2025, 20:00 ET Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program
Therapeutics (www.onward-therapeutics.com) is a clinical-stage biotechnology company focused on developing innovative cancer therapies. Led by a seasoned team in translational science and drug development, the company advances
More news about: Onward Therapeutics SA
Oct 27, 2025, 19:38 ET Class Action Reminder: ATYR Investors Should Contact Robbins LLP for Information About Leading the aTyr Pharma, Inc. Class Action Lawsuit
DIEGO, Oct. 27, 2025 /PRNewswire/ -- Company: aTyr Pharma, Inc. (NASDAQ: ATYR) is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
More news about: Robbins LLP
Oct 27, 2025, 16:46 ET Draper Receives $25 Million in State and Local Funding for Construction of Its New IMPACT Center in Lowell
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Oct 27, 2025, 16:05 ET Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 27, 2025, 16:03 ET BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Oct 27, 2025, 14:27 ET Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and
More news about: Syngene International
Oct 27, 2025, 14:08 ET Plastomics Announces Initial Close of Series B Financing to Advance Groundbreaking Corn Chloroplast Transformation Technology
ST. LOUIS, Oct. 27, 2025 /PRNewswire/ -- Plastomics, a cutting-edge leader in agricultural biotechnology, recently announced the successful initial close of its Series B funding round. The company secured $5.8 million to fuel the next wave of innovation
More news about: Plastomics
Oct 27, 2025, 14:00 ET Lilly declares fourth-quarter 2025 dividend
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 27, 2025, 14:00 ET Cizzle Bio CEO Bill Behnke Moderates High-Profile Panel on Value-Based Cancer Diagnostics at 2025 AVBCC Summit
providers. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric
More news about: Cizzle Bio
Oct 27, 2025, 13:00 ET Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 27, 2025, 13:00 ET Ten Rubin Rudman Partners Named to 2026 Lawdragon 500 Leading Family Lawyers in America
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Oct 27, 2025, 10:50 ET Global Optogenetics Equipment Market Valued at USD 400 Million in 2024, Projected to Reach USD 1.2 Billion by 2033, Growing at a 15.5% CAGR from 2026 to 2033 - Market Research Intellect
in neurodegenerative disease research, such as Alzheimer's and Parkinson's, is fueling global demand. Universities, research institutions, and biotechnology firms are investing heavily in this domain to develop advanced optogenetic systems, including lasers, light delivery devices, and control software.
More news about: Market Research Intellect
Oct 27, 2025, 10:45 ET Engineered Stone Market is expected to generate a revenue of USD 43.2 Billion by 2031, Globally, at 5.50% CAGR: Verified Market Research®
Application (Research Applications, Clinical & Diagnostics Applications), By End-User (Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies), By Geographic Scope And Forecast
More news about: Verified Market Research